Tag: Zydus
-
Zydus Life shares rise as US arm gains rights for rare paediatric disease drug
Shares of the company have risen 52.45 percent so far this year. Zydus Lifesciences gained 1.6 percent after its US arm Sentynl Therapeutics assumed full responsibility for the development and commercialisation of CUTX-101, which is used in the treatment of Menkes disease, from Cyprium Therapeutics. Sentynl announced the execution of an assignment and assumption agreement…